PersonExecutiveScientist
John McHutchison
John McHutchison, AO, MD is the CEO and Chairman of Tune Therapeutics, a pioneering epigenome editing company based in Durham, NC. An internationally acclaimed hepatologist and drug developer, McHutchison spent nearly a decade at Gilead Sciences as Chief Scientific Officer, where he led the development of transformative hepatitis C cures used by over 3.2 million people worldwide, including Sovaldi and Harvoni. Now at Tune, he is steering the company's TEMPO epigenome editing platform toward a new era of precision medicine for chronic and complex diseases.
epigeneticsgene therapybiotechnologyhepatitis chepatologyceo
